https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42037 Wed 17 Aug 2022 12:13:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23860 Sat 24 Mar 2018 07:12:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44538 Mon 17 Oct 2022 09:03:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52509 Mon 16 Oct 2023 10:31:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23970 -1 (mean: 564 mg; 95% confidence interval 431-696 mg). Median buprenorphine dose was 12.0 mg (interquartile range 9.5 mg, range 4-32 mg) at day 7 and 16.0 mg (interquartile range 13.5 mg, range 4-32 mg) at day 28. Buprenorphine doses received were markedly higher than estimated codeine doses based on standard dose conversion tables.Discussion and Conclusions: With increasing presentations relating to codeine dependence, these findings provide important guidance to clinicians. Buprenorphine doses were consistently higher than doses estimated based on the dose of codeine consumed, and were comparable with doses used in the treatment of dependence with heroin and more potent prescription opioids.]]> Fri 01 Apr 2022 09:28:10 AEDT ]]>